Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients.

ABSTRACT:

Objective

To report on safety and effectiveness of subcutaneous cladribine (Litak^®) in multiple sclerosis (MS) patients.

Methods

Litak^® was offered to MS-patients irrespective of disease course. Litak^® 10 mg was administered for 3-4 days during week 1. Based on lymphocyte count at week 4, patients received another 0-3 doses at week 5. A second course was administered 11 months later. Follow-up included adverse events, relapses, expanded disability status scale (EDSS), 9-hole-peg and Timed-25-foot-walking tests, no-evidence-of-disease-activity (NEDA), no-evidence-of-progression-or-active-disease (NEPAD), MRI, cerebrospinal fluid (CSF) neurofilament light chain (NfL), and lymphocyte counts.

Results

In all, 208 patients received at least

SUBMITTER: Allen-Philbey K 

PROVIDER: S-EPMC8842147 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature